Eluminex Biosciences Closes $40+ Million Series B Financing To Continue The Development Of Innovative Ophthalmic Assets And Recombinant Human Collagen Technology

Feb 27, 2023•almost 3 years ago

Amount Raised

$40 Million

Round Type

series b

SuzhouBiotechnology

Investors

Oriza Holdings3 E Bioventures CapitalGuangzhou Yuexiu Industrial Investment Fund ManagementCenova Capital

Description

Eluminex Biosciences (Suzhou) Limited (Eluminex) officially announced today the closing of a Series B financing of over $40 million (USD). Financing was led by Cenova Capital with additional participation from Guangzhou Yuexiu Industrial Investment Fund Management, 3E Bioventures Capital, Oriza Holdings, and Series A investors.

Company Information

Company

Eluminex Biosciences

Location

Suzhou, Jiangsu, China

About

Founded in February 2020, Eluminex Biosciences (Suzhou) Limited is a global biotechnology company focusing on ophthalmic diseases and recombinant human collagen technology. The company's headquarters and research and development center are located in BioBAY of Suzhou Industrial Park, with a US-campus based in South San Francisco, California. For more information, visit www.eluminexbio.com.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends